Therefore, we treated glioma stem cell lines, GSC1228, GSC222, and GSC316, which express stemness markers (MYC, Nestin, and SOX2)(Supplementary Fig. S1C, D) and possess the potential for self-renewal, differentiation, and tumor-initiating capacity [7, 41], with S2101, S2157, and S2172 for 96 h and evaluated the growth inhibitory effect. The gene discussed is SOX2; the disease is central nervous system cancer.